FIELD: medical engineering; medicine.
SUBSTANCE: capsule contains antigen material and is manufactured from polyacrylamide gel produced in vivo with preferential cell size of 0.4-0.8 mcm surrounded and coalesced with recipient connective tissue membrane. The antigen material is introduced into polyacrylamide gel after forming connective tissue membrane. The capsule is usable for forming prolonged immune response also to tumor antigens.
EFFECT: super long antigen material exposure under in vivo conditions.
19 cl, 3 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LASER VACCINATION METHOD FOR PATIENTS SUFFERING FROM METASTATIC CANCER TYPE | 2005 |
|
RU2345788C2 |
| VACCINE COMPOSITIONS, METHODS FOR APPLICATION THEREOF IN MELANOMA PREVENTION AND TREATMENT, AND GENETIC CONSTRUCTIONS FOR OBTAINING ACTIVE SUBSTANCES OF COMPOSITION | 2006 |
|
RU2333767C2 |
| PROTEIN-PEPTIDE ANTITUMOR COMPOSITION, CELL PREPARATION ACTIVATED THEREWITH AND METHOD FOR TUMOR PROPHYLAXIS OR TREATMENT | 2004 |
|
RU2283129C1 |
| METHOD FOR PRODUCING LIVE CELL VACCINE FOR BREAST CANCER PREVENTION | 2008 |
|
RU2407789C2 |
| VACCINE FOR ANTITUMOR IMMUNITY STIMULATION | 2000 |
|
RU2192884C2 |
| ANTIGENIC COMPOSITION AND THERAPEUTIC APPLICATION THEREOF FOR PREVENTING AND TREATING ONCOLOGICAL DISEASES, RECOMBINANT PLASMID DNA, PROVIDING SYNTHESIS OF HYBRID PROTEIN, AS WELL AS METHOD OF PRODUCING PROTEIN | 2013 |
|
RU2590701C2 |
| COMPOSITIONS CAUSING SPECIFIC RESPONSE OF CYTOTOXIC T-LYMPHOCYTES, INCLUDING LYMPH-ABLATIVE COMPOUND AND MOLECULE WHICH CONTAINS ANTIGEN SEQUENCES AND IS TARGETED AT SPECIALISED ANTIGEN-PRESENTING CELLS | 2007 |
|
RU2448729C2 |
| INDIVIDUALISED VACCINES FOR CANCER | 2012 |
|
RU2670745C9 |
| METHOD FOR MURINE MELANOMA LYMPHATIC AND HEMATOGENOUS METASTASIS B SIMULATION FOR NONLINEAR WHITE RATS | 2016 |
|
RU2615908C1 |
| METHOD FOR INHIBITION OF MELANOMA GROWTH IN TUMOUR-BEARING MICE | 2023 |
|
RU2813701C2 |
